Market Research Reports

Preimplantation Genetic Diagnosis Market (Test Type - PGD for Chromosomal Aberrations, Aneuploidy Screening, Gender Selection, Single Gene Disorders, HLA Typing and X-linked Diseases) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020

84pages
Published Date: 2014-10-30
 

Description



Since the last two decades, preimplantation genetic diagnosis (PGD) has been used to detect chromosomal aneuploidy in low prognosis patients who undergo in-vitro fertilization (IVF). PGD is now being used to detect a broader range of indications due to advancements in the medical technology. These indications include chromosomal aberrations, genetic abnormalities, gender selection, HLA typing, X-linked diseases and single gene diseases. Demand for PGD is continuously increasing in patients who undergo IVF in the hope that it would improve the probability of live birth and reduce the chances of disabilities and genetic disorders in the offspring. 

This report provides in-depth analysis of the preimplantation genetic diagnosis market and its test types across various regions. Stakeholders in the report include diagnostic laboratories that provide PGD services, companies involved in the production of diagnosis kits and sequencers for PGD, and prospective market players planning to enter the market. The report comprises executive summary, which offers a market snapshot that covers the overall information about various types of tests in the PGD market.  

The market overview section explains market dynamics such as drivers, restraints and opportunities that influence the current and future status of the preimplantation genetic diagnosis market. Impact factors such as market attractiveness analysis and regulatory framework of PGD in various countries has been included in this section in order to provide a thorough analysis of the overall competitive scenario of the global preimplantation genetic diagnosis market. The report covers competitive analysis, which includes heat map analysis by key market players. Through heat map analysis, the stakeholder would be able to identify the presence of players across various segments of the market. All these factors would help market players gain a thorough understanding of the overall competitive scenario. The market players can then decide upon the business strategies and plans to be implemented in order to strengthen their position in the global market.  

The global preimplantation genetic diagnosis market has been differentiated based on the types of tests and geographies. Based on the types of tests, the global preimplantation genetic diagnosis market has been segmented into six categories: PGD for chromosomal aberrations, aneuploidy screening, X-linked diseases, single gene disorder, HLA typing and gender selection. A detailed market analysis of the segments mentioned above has been provided at the global level in this study. The market analysis is based on market size and forecast in terms of USD million for the period 2013 to 2020 along with the compounded annual growth rate (CAGR %) for the period 2014 to 2020, considering 2013 as the base year.

Geographically, the global preimplantation genetic diagnosis market has been categorized into four regions: North America, Europe, Asia Pacific and Rest of the World (RoW). This section further provides market size and forecast for various types of PFD tests in each region. The market size and forecast of the regional markets is provided for the period 2012 to 2020. CAGR (%) for each region is also estimated for the period 2014 to 2020, considering 2013 as the base year. The report also includes strategic recommendations, which would help market players sustain and grow in the highly competitive market. These recommendations would also help new entrants establish a strong position in the global preimplantation genetic diagnosis market.

Company profiles section comprises key information such as company overview, financial overview, product portfolio, business strategies and recent developments about major players operating in the preimplantation genetic diagnosis market. Key players profiled in the report include Genesis Genetics, Genea Ltd., Illumina, Inc., Laboratory Corporation of America Holdings, Natera, Inc., PerkinElmer, Inc., Quest Diagnostics, Inc., Reprogenetics LLC and Reproductive Genetics Institute.

The global preimplantation genetic diagnosis market is segmented into the following categories:

Preimplantation Genetic Diagnosis Market, by Test Type
  • PGD for Chromosomal Aberrations
  • PGD for Aneuploidy Screening
  • PGD for Gender Selection
  • PGD for Single Gene Disorder
  • PDG for HLA Typing
  • PGD for X-linked Diseases
Preimplantation Genetic Diagnosis Market, by Geography
  • North America
    • PGD for Chromosomal Aberrations
    • PGD for Aneuploidy Screening
    • PGD for Gender Selection
    • PGD for Single Gene Disorder
    • PDG for HLA Typing
    • PGD for X-linked Diseases
  • Europe
    • PGD for Chromosomal Aberration
    • PGD for Aneuploidy Screening
    • PGD for Gender Selection
    • PGD for Single Gene Disorder
    • PDG for HLA Typing
    • PGD for X-linked Diseases
  • Asia Pacific
    • PGD for Chromosomal Aberrations
    • PGD for Aneuploidy Screening
    • PGD for Gender Selection
    • PGD for Single Gene Disorder
    • PDG for HLA Typing
    • PGD for X-linked Diseases
  • Rest of the World (RoW)
    • PGD for Chromosomal Aberrations
    • PGD for Aneuploidy Screenin
    • PGD for Gender Selection
    • PGD for Single Gene Disorder
    • PDG for HLA Typing
    • PGD for X-linked Diseases

Table of Contents



Chapter 1 Introduction
1.1 Report Description
1.2 Market Segmentation
1.4 Research Methodology
1.5 List of Abbreviations

Chapter 2 Executive Summary
2.1 Market Snapshot: Global Preimplantation Genetic Diagnosis Market
2.2 Comparative Analysis: Global Preimplantation Genetic Diagnosis Market, by Geography, 2013 & 2020 (Value %)

Chapter 3 Global Preimplantation Genetic Diagnosis Market Overview
3.1 Introduction
     3.1.1 Preimplantation Genetic Diagnosis Process
     3.1.2 Preimplantation Genetic Diagnosis Applications
3.2 Market Dynamics
     3.2.1 Market Drivers
             3.2.1.1 Delay in conception results in increased demand of PGD among higher age women
             3.2.1.2 Increasing incidence rates of genetic diseases influencing patients to undergo PGD cycles for disease free offspring
             3.2.1.3 Lifestyle hazards such as smoking, stress and pollution are leading to decreased fertility resulting in increased demand for IVF and PGD
     3.2.2 Market Restraints
             3.2.2.1 Economic and social factors associated with IVF restrains the PGD market
             3.2.2.2 Limited insurance coverage for IVF and PGD results in less patient pool
     3.2.3 Market Opportunities
             3.2.3.1 Innovation in cancer prevention will increase the demand for PGD during forecast period
             3.2.3.2 Advancement in the field of genetics will propel the growth of PGD market
3.3 Regulatory Framework: Preimplantation Genetic Diagnosis
3.4 Porter’s Five Forces Analysis for the Global Preimplantation Genetic Diagnosis Market
     3.4.1 Bargaining Power of Suppliers
     3.4.2 Bargaining Power of Buyers
     3.4.3 Threat of New Entrants
     3.4.4 Threat of Substitutes
     3.4.5 Competitive Rivalry
3.5 Market Attractiveness Analysis: Global Preimplantation Genetic Diagnosis Market, by Geography
3.6 Competitive Landscape
     3.6.1 Heat Map Analysis for Key Market Players of Global Preimplantation Genetic Diagnosis Market

Chapter 4 Global Preimplantation Genetic Diagnosis Market, by Test Type
4.1 Overview
     4.1.1 Global Preimplantation Genetic Diagnosis Market Revenue, by Test Type, 2012 – 2020 (USD Million)
4.2 Comparative Analysis: Global Preimplantation Genetic Diagnosis Market, by Test Type, 2013 & 2020 (Value %)
4.3 PGD for Chromosomal Aberrations
     4.3.1 Global PGD for Chromosomal Aberrations Market Revenue, 2012 – 2020 (USD Million)
4.4 PGD for Aneuploidy Screening
     4.4.1 Global PGD for Aneuploidy Screening Market Revenue, 2012 – 2020 (USD Million)
4.5 PGD for Gender Selection
     4.5.1 Global PGD for Gender Selection Market Revenue, 2012 – 2020 (USD Million)
4.6 PGD for Single Gene Disorder
     4.6.1 Global PGD for Single Gene Disorder Market Revenue, 2012 – 2020 (USD Million)
4.7 PGD for HLA Typing
     4.7.1 Global PGD for HLA Typing Market Revenue, 2012 – 2020 (USD Million)
4.8 PGD for X-linked diseases
     4.8.1 Global PGD for X-linked Diseases Market Revenue, 2012 – 2020 (USD Million)

Chapter 5 Preimplantation Genetic Diagnosis Market, by Geography
5.1 Overview
     5.1.1 Global Preimplantation Genetic Diagnosis Market Revenue, by Geography, 2012 – 2020 (USD Million)
5.2 North America
     5.2.1 North America Preimplantation Genetic Diagnosis Market Revenue, 2012 – 2020 (USD Million)
     5.2.2 North America Preimplantation Genetic Diagnosis Market Revenue, by Test Type, 2012 – 2020 (USD Million)
5.3 Europe
     5.3.1 Europe Preimplantation Genetic Diagnosis Market Revenue, 2012 – 2020 (USD Million)
     5.3.2 Europe Preimplantation Genetic Diagnosis Market Revenue, by Test Type, 2012 – 2020 (USD Million)
5.4 Asia Pacific
     5.4.1 Asia Pacific Preimplantation Genetic Diagnosis Market Revenue, 2012 – 2020 (USD Million)
     5.4.2 Asia Pacific Preimplantation Genetic Diagnosis Market Revenue, by Test Type, 2012 – 2020 (USD Million)
5.5 Rest of the World (RoW)
     5.5.1 Rest of the World Preimplantation Genetic Diagnosis Market Revenue, 2012 – 2020 (USD Million)
     5.5.2 Rest of the World Preimplantation Genetic Diagnosis Market Revenue, by Test Type, 2012 – 2020 (USD Million)

Chapter 6 Recommendations
6.1 Introduction of Innovative Technologies to Reduce the Cost of Equipment and Procedure
6.2 Draw from Rapidly Growing CRAMS Market in Emerging Economies

Chapter 7 Company Profiles
7.1 Genesis Genetics
     7.1.1 Company Overview
     7.1.2 Financial Overview
     7.1.3 Product Portfolio
     7.1.4 Business Strategies
     7.1.5 Recent Developments
7.2 Genea Ltd.
     7.2.1 Company Overview
     7.2.2 Financial Overview
     7.2.3 Product Portfolio
     7.2.4 Business Strategies
     7.2.5 Recent Developments
7.3 Illumina, Inc.
     7.3.1 Company Overview
     7.3.2 Financial Overview
     7.3.3 Product Portfolio
     7.3.4 Business Strategies
     7.3.5 Recent Developments
7.4 Laboratory Corporation of America Holdings (LabCorp)
     7.4.1 Company Overview
     7.4.2 Financial Overview
     7.4.3 Product Portfolio
     7.4.4 Business Strategies
     7.4.5 Recent Developments
7.5 Natera, Inc.
     7.5.1 Company Overview
     7.5.2 Financial Overview
     7.5.3 Product Portfolio
     7.5.4 Business Strategies
     7.5.5 Recent Developments
7.6 PerkinElmer, Inc.
     7.6.1 Company Overview
     7.6.2 Financial Overview
     7.6.3 Product Portfolio
     7.6.4 Business Strategies
     7.6.5 Recent Developments
7.7 Quest Diagnostics, Inc.
     7.7.1 Company Overview
     7.7.2 Product Portfolio
     7.7.3 Financial Overview
     7.7.4 Business Strategies
     7.7.5 Recent Developments
7.8 Reprogenetics LLC
     7.8.1 Company Overview
     7.8.2 Financial Overview
     7.8.3 Product Portfolio
     7.8.4 Business Strategies
     7.8.5 Recent Developments
7.9 Reproductive Genetics Institute
     7.9.1 Company Overview
     7.9.2 Financial Overview
     7.9.3 Product Portfolio
     7.9.4 Business Strategies
     7.9.5 Recent Developments

List of Figures

FIG. 1 Preimplantation Genetic Diagnosis Market Segmentation
FIG. 2 Global Preimplantation Genetic Diagnosis Market, by Test Type, 2013 (USD Million)
FIG. 3 Comparative Analysis: Global Preimplantation Genetic Diagnosis Market, by Geography, 2013 & 2020 (Value %)
FIG. 4 Preimplantation Genetic Diagnosis Process
FIG. 5 Porter’s Five Forces Analysis for the Global Preimplantation Genetic Diagnosis Market
FIG. 6 Market Attractiveness Analysis of the Global Preimplantation Genetic Diagnosis Market, by Geography
FIG. 7 Heat Map Analysis for Key Market Players of Global Preimplantation Genetic Diagnosis Market
FIG. 8 Comparative Analysis of the Global Preimplantation Genetic Diagnosis Market, by Test Type, 2013 & 2020 (%)
FIG. 9 Global PGD for Chromosomal Aberrations Market Revenue, 2012 – 2020 (USD Million)
FIG. 10 Global PGD for Aneuploidy Screening Market Revenue, 2012 – 2020 (USD Million)
FIG. 11 Global PGD for Gender Selection Market Revenue, 2012 – 2020 (USD Million)
FIG. 12 Global PGD for Single Gene Disorder Market Revenue, 2012 – 2020 (USD Million)
FIG. 13 Global PGD for HLA Typing Market Revenue, 2012 – 2020 (USD Million)
FIG. 14 Global PGD for X-linked Diseases Market Revenue, 2012 – 2020 (USD Million)
FIG. 15 North America Preimplantation Genetic Diagnosis Market Revenue, 2012 – 2020 (USD Million)
FIG. 16 Europe Preimplantation Genetic Diagnosis Market Revenue, 2012 – 2020 (USD Million)
FIG. 17 Asia Pacific Preimplantation Genetic Diagnosis Market Revenue, 2012 – 2020 (USD Million)
FIG. 18 Rest of the World Preimplantation Genetic Diagnosis Market Revenue, 2012 – 2020 (USD Million)
FIG. 19 Illumina, Inc.: Annual Revenue, 2011 – 2013 (USD Million)
FIG. 20 LabCorp: Annual Revenue, 2011 – 2013 (USD Million)
FIG. 21 PerkinElmer Inc.: Annual Revenue, 2011 – 2013 (USD Million)
FIG. 22 Quest Diagnostics: Annual Revenue, 2011 – 2013 (USD Million)

List of Tables

TABLE 1 List of Abbreviations
TABLE 1 Market Snapshot: Global Preimplantation Genetic Diagnosis Market
TABLE 2 Global Preimplantation Genetic Diagnosis Market Revenue, by Test Type, 2012 – 2020 (USD Million)
TABLE 3 Global Preimplantation Genetic Diagnosis Market Revenue, by Geography, 2012 – 2020 (USD Million)
TABLE 4 North America Preimplantation Genetic Diagnosis Market Revenue, by Test Type, 2012 – 2020 (USD Million)
TABLE 5 Europe  Preimplantation Genetic Diagnosis Market Revenue, by Test Type, 2012 – 2020 (USD Million)
TABLE 6 Asia Pacific Preimplantation Genetic Diagnosis Market Revenue, by Test Type, 2012 – 2020 (USD Million)
TABLE 7 Rest of the World Preimplantation Genetic Diagnosis Market Revenue, by Test Type, 2012 – 2020 (USD Million)

Market Overview




Enquiry Before Buying


Free Market Analysis


Preimplantation genetic diagnosis (PGD) is an adjuvant technique to in vitro fertilization (IVF) for detecting genetic diseases or conditions before the implantation of embryo. PGD can be performed for screening of a range of medical conditions such as Down’s syndrome, inheritable diseases and traits of other physiological abnormality. Increasing patient awareness about PGD technique and rising prevalence of genetic disorders among infants has led to the rise in demand for PGD along with IVF procedure. The combination of PGD and IVF  has improved the rate of successful pregnancy due to reduced chances of passing the undesired genetic material in the embryo.

The use of array comparative genomic hybridization (aCGH) and fluorescent in situ hybridization (FISH) techniques in PGD has improved the process efficiency and success rate of pregnancy through IVF. Demand for PGD, however, is dependent on the regulations governing infertility procedures in various countries. PGD for gender selection and HLA typing is banned in most parts of Asia, whereas it is regulated in the U.S. and in some parts of the European Union. Regulatory impact plays a major role in analyzing the global preimplantation genetic diagnosis market.

Based on the type of test, the global preimplantation genetic diagnosis market has been categorized into six segments: PGD for chromosomal aberrations, PGD for aneuploidy screening, PGD for gender selection, PGD for single gene disorder, PDG for HLA typing and PGD for X-linked diseases. PGD for aneuploidy screening held the highest share in 2013 as aneuploidy could lead to severe abnormalities. Aneuploidy screening reduces the probability of transferring an embryo with chromosomal abnormality. . Aneuploidy screening during prenatal testing has a major disadvantage; if the chromosomal abnormality were detected in the fetus, the pregnancy would be terminated. However, this drawback is efficiently overcome by opting for preimplantation genetic diagnosis, since genetic screening for aneuploidy is performed before the embryo is implanted and pregnancy is conceived.

Geographically, the global preimplantation genetic diagnosis market has been categorized into four regions: North America, Europe, Asia Pacific and Rest of the World (RoW). Each geographical market has been further analyzed based on the types of test. Europe dominated the global preimplantation genetic diagnosis market in 2013 due to increasing patient awareness and high number of IVF cycles being performed in the region. Conversely, North America is expected to grow at a higher CAGR during the forecast period due to rapid increase in the number of IVF cycles being performed and the rising disability rate due to increase in smoking. Moreover, high cost of the gender selection procedure and rising demand for identifying and selecting the gender by mothers increases the market share of PGD in gender selection. Restrictions on gender selection and detection of X-linked diseases in developing regions such as Asia Pacific, Latin America and Africa restrain the growth of the PGD market. Moreover, lack of patient awareness and inadequate healthcare facilities in the developing economies of these regions limit the use of PGD in HLA typing and detection of single gene disorder.

The global preimplantation genetic diagnosis market is characterized by the presence of some of the major companies including Genesis Genetics, Genea Ltd., Illumina, Inc., Laboratory Corporation of America Holdings, Natera, Inc., PerkinElmer, Inc., Quest Diagnostics, Inc., Reprogenetics LLC and Reproductive Genetics Institute. Market players are in constant endeavor to improve their technologies in genetic testing in order to enhance the efficiency and provide better services to healthcare practitioners.

preimplantation-genetic-diagnosis-market

 

To get discount on this report, just click on the button below.

To receive brochure, please click on the button below.

Share This Market Study!  

Upcoming Report

Payment
Copyright @ Transparency Market Research